A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

Currently, four second-generation anti-CD19 CAR T-cell products are commercially available and approved for the treatment of several B-cell lymphomas. 1-9 These therapies incorporate either a 4 ...